

Curriculum Vitae

Watz, Henrik Prof. Dr. med.
d.o.b. October 07th, 1971, in Rotenburg/Fulda, Germany

University Education

2012 Habilitation Internal Medicine, University of Kiel
2001 Doctorate Medicine, Justus-Liebig-University Giessen
1991-1998 Studies of Medicine, Justus-Liebig-University Giessen

Scientific Career

Since 2026 Professor of Clinical Research in Respiratory Medicine, University of Lübeck
University Hospital Schleswig-Holstein, Campus Lübeck
2024-2025 Medical Director Velocity Clinical Research Germany, former Pulmonary Research
Institute at LungenClinic Grosshansdorf,
2008-2023 Managing Partner and PI Pulmonary Research Institute at LungenClinic Grosshansdorf
Since 2024 Co-Chair European Respiratory Society “Task force physical activity in chronic lung
disease”
2023-2026 Co-Chair COPD Specialist Guideline of the German Respiratory Society
Since 2023 Disease Area Coordinator COPD, German Center for Lung Research (DZL)
2023-2025 Member American Thoracic Society Task Force on Home-based monitoring using
spirometry and pulse oximetry in adults with chronic lung disease
Since 2022 PI and Member TOLIFE, Combining Artificial Intelligence and smart sensing TOward
better management and improved quality of LIFE in chronic obstructive pulmonary
disease , EU-funded project under HORIZON-HLTH-2021-DISEASE-04-04
2021-2025 Medical Lead TELEMENTOR COPD (“TELEMEdizinisches MoNiTORing”) Innovationfund
of the German Statutory Health Insurance System/ Federal Ministry of Health
2020-2022 Associate Editor Eur J Intern Med
Since 2019 Founding Member and National Lead CICERO (Clinical research collaboration on
COPD exacerbations) funded by the European Respiratory Society
2019-2025 PI and Member MOBILISE-D to validate digital mobility as an outcome in clinical trials;
EU-funded project by the HORIZON 2020 program and EFPIA-partners
Since 2018 Member of the COPD-Biomarker Qualification Consortium (CBQC)
Since 2018 COPD expert for the German National Cohort (NAKO Gesundheitskohorte)
Since 2017 Delegate of the German Respiratory Society for the National German COPD
guideline
2017–2020 Task Force Member Mobile Health, German Society for Internal Medicine
2017-2022 Member Editorial Board Eur Respir J
2017-2022 Member Editorial Board Am J Respir Crit Care Med
Since 2017 Board of Chairs German Association for Outpatient Pulmonary Rehabilitation
Since 2017 Board of Chairs German Respiratory League (Atemwegsliga)
2015-2022 Associate Editor The Clinical Respiratory Journal
2012-2015 Academic Editor PLOS ONE
2012-2014 Co-Chair, European Respiratory Society Task Force “Physical activity in COPD”
Since 2011 Board of Chairs COSYCONET (Systemic consequences of COPD network)
Since 2011 Principal Investigator Disease Area COPD and Asthma, German Center for Lung
Research (DZL)
2005-2008 Internship and Residency, Internal and Respiratory Medicine, LungenClinic
Grosshansdorf
2003-2004 Internship and Residency, Internal Medicine, University Hospital Frankfurt
2000-2002 Internship and Residency, Respiratory Medicine, Greifenstein

1998–2000 Internship and Residency, Department of Radiology, University of Giessen

Awards and Honors

2018 Reviewer Award Am J Respir Crit Care Med
2011 Award German Respiratory Society
2005 Award Western German Respiratory Society (Curt-Dehner-Stiftung)
2003 Award German Lung Foundation

Citation Record

Total citations: 17,755; h-index 66; h-index since 2021 50 (Google Scholar 30 Mar 2026)

Top-10 selected Publications

Andreas S, Testa M, Boyer L, Brusselle G, Janssens W, Kerwin E, Papi A, Pek B, Puente-Maestu L, Saralaya D, **Watz H**, Wilkinson TMA, Casula D, Di Maro G, Lattanzi M, Moraschini L, Schoonbroodt S, Tasciotti A, Arora AK, Maltais F; NTHi-Mcat-002 study group. Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial. **Lancet Respir Med**. 2022 May;10(5):435-446. doi: [10.1016/S2213-2600\(21\)00502-6](https://doi.org/10.1016/S2213-2600(21)00502-6).

Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A, **Watz H**, Castro M, Nenasheva NM, Tohda Y, Langton D, Cardona G, Domingo C, Park HS, Chapman KR, Mao X, Zhang Y, Khan AH, Deniz Y, Rowe PJ, Kapoor U, Khokhar FA, Mannent LP, Ruddy M, Laws E, Amin N, Hardin M. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. **Lancet Respir Med**. 2022 Jan;10(1):11-25. doi: [10.1016/S2213-2600\(21\)00322-2](https://doi.org/10.1016/S2213-2600(21)00322-2)

Waschki B, Alter P, Zeller T, Magnussen C, Neumann JT, Twerenbold R, Sinning C, Herr C, Kahnert K, Fährndrich S, Blankenberg S, Rabe KF, Welte T, Jörres RA, Vogelmeier CF, Bals R, **Watz H**; German COSYCONET Cohort. High-sensitivity troponin I and all-cause mortality in patients with stable COPD: an analysis of the COSYCONET study. **Eur Respir J**. 2020 Feb 27;55(2):1901314. doi: [10.1183/13993003.01314-2019](https://doi.org/10.1183/13993003.01314-2019).

Rabe KF, **Watz H**, Baraldo S, Pedersen F, Biondini D, Bagul N, Hanauer G, Göhring UM, Purkayastha D, Román J, Alagappan VKT, Saetta M. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial. **Lancet Respir Med**. 2018 Nov;6(11):827-836. doi: [10.1016/S2213-2600\(18\)30331-X](https://doi.org/10.1016/S2213-2600(18)30331-X).

Houben-Wilke S, Jörres RA, Bals R, Franssen FM, Gläser S, Holle R, Karch A, Koch A, Magnussen H, Obst A, Schulz H, Spruit MA, Wacker ME, Welte T, Wouters EF, Vogelmeier C, **Watz H**. Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences-Comorbidities Network Study. **Am J Respir Crit Care Med**. 2017 Jan 15;195(2):189-197. doi: [10.1164/rccm.201602-0354OC](https://doi.org/10.1164/rccm.201602-0354OC).

Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, Vogelmeier C, Fabbri LM, Chanez P, Dahl R, Disse B, Finnigan H, Calverley PM. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. **Lancet Respir Med**. 2016 May;4(5):390-8. doi: [10.1016/S2213-2600\(16\)00100-4](https://doi.org/10.1016/S2213-2600(16)00100-4).

Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, **Watz H**, Tetzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, Chanez P, Wouters EF, Calverley PM; WISDOM Investigators. Withdrawal of inhaled

glucocorticoids and exacerbations of COPD. **N Engl J Med.** 2014 Oct 2;371(14):1285-94. doi: [10.1056/NEJMoa1407154](https://doi.org/10.1056/NEJMoa1407154).

Watz H, Pitta F, Rochester CL, Garcia-Aymerich J, ZuWallack R, Troosters T, Vaes AW, Puhan MA, Jehn M, Polkey MI, Vogiatzis I, Clini EM, Toth M, Gimeno-Santos E, Waschki B, Esteban C, Hayot M, Casaburi R, Porszasz J, McAuley E, Singh SJ, Langer D, Wouters EF, Magnussen H, Spruit MA. An official European Respiratory Society statement on physical activity in COPD. **Eur Respir J.** 2014 Dec;44(6):1521-37. doi: [10.1183/09031936.00046814](https://doi.org/10.1183/09031936.00046814).

Watz H, Barnacle H, Hartley BF, Chan R. Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. **Lancet Respir Med.** 2014 Jan;2(1):63-72. doi: [10.1016/S2213-2600\(13\)70200-5](https://doi.org/10.1016/S2213-2600(13)70200-5).

Watz H, Waschki B, Boehme C, Claussen M, Meyer T, Magnussen H. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. **Am J Respir Crit Care Med.** 2008 Apr 1;177(7):743-51. doi: [10.1164/rccm.200707-1011OC](https://doi.org/10.1164/rccm.200707-1011OC).